Valuation: PFIZER

Market Cap 16TCr 0 13TCr 13TCr 11TCr 22TCr 14,85900Cr 22TCr 1,48100Cr 58TCr 7,44400Cr 58TCr 57TCr 24,78100Cr P/E 2026 *
17.1x
P/E 2027 * 13.3x
Enterprise Value 20TCr 0 18TCr 16TCr 15TCr 28TCr 19,40200Cr 29TCr 1,93300Cr 76TCr 9,71900Cr 76TCr 74TCr 32,35700Cr EV / Sales 2026 *
3.26x
EV / Sales 2027 * 3.31x
Free-Float
59.05%
Yield 2026 *
6.32%
Yield 2027 * 6.37%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 55 16/08/2026
Compliance Officer 65 01/12/2013
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+3.60%-0.50%+74.80%+127.97% 1,05500Cr
+3.33%+3.55%+53.48%+55.80% 63TCr
+3.43%+4.42%+25.27%+72.59% 44TCr
+1.35%-3.27%+40.98%+39.91% 35TCr
+1.75%-0.98%+26.20%+39.73% 29TCr
+2.13%-1.53%+1.85%+9.40% 24TCr
+1.41%+1.94%+43.45%+61.18% 23TCr
+1.35%-3.20%-9.07%-53.51% 20TCr
+3.25%+7.80%+21.18%+87.50% 17TCr
Average +1.14%-1.44%+30.90%+48.95% 40.14TCr
Weighted average by Cap. +0.48%-1.87%+43.73%+68.76%

Financials

2026 *2027 *
Net sales 6.22TCr 0 5.38TCr 5.06TCr 4.6TCr 8.65TCr 5,95400Cr 8.79TCr 59TCr 23TCr 2,98300Cr 23TCr 23TCr 9,93000Cr 5.98TCr 0 5.17TCr 4.86TCr 4.42TCr 8.32TCr 5,72500Cr 8.45TCr 57TCr 22TCr 2,86800Cr 22TCr 22TCr 9,54700Cr
Net income 890.05Cr 0 768.85Cr 723.02Cr 657.6Cr 1.24TCr 85TCr 1.26TCr 8.49TCr 3.32TCr 43TCr 3.34TCr 3.27TCr 1,42000Cr 1.11TCr 0 957.14Cr 900.09Cr 818.65Cr 1.54TCr 1,06000Cr 1.56TCr 11TCr 4.13TCr 53TCr 4.16TCr 4.07TCr 1,76800Cr
Net Debt 4.75TCr 0 4.1TCr 3.86TCr 3.51TCr 6.6TCr 4,54300Cr 6.71TCr 45TCr 18TCr 2,27600Cr 18TCr 17TCr 7,57600Cr 4.29TCr 0 3.7TCr 3.48TCr 3.17TCr 5.96TCr 4,10300Cr 6.06TCr 41TCr 16TCr 2,05500Cr 16TCr 16TCr 6,84200Cr
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A